Breast Cancer

Statistically and clinically meaningful improvements in invasive disease-free survival were observed among patients with hormone receptor–positive/HER2-negative early breast cancer who received ribociclib in addition to endocrine therapy.

Patients with metastatic breast cancer who received ribociclib plus fulvestrant achieved a median progression-free survival of 18.1 months vs 5.29 months with placebo/fulvestrant.

The FDA has granted priority review status to a breast cancer optical imaging agent, Lumisight.

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

The FDA has issued a complete response letter for vic-trastuzumab duocarmazine.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.

Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.

Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.

Using established guidelines to monitor and intervene early for diarrhea and neutropenia may result in longer treatment durations and sustained benefit from sacituzumab govitecan.

The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.

Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.

Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.

The US Preventive Services Task Force is working on a draft recommendation which would lower the age of breast cancer screenings from 50 years to 40 years for women at average risk.

Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

Applying the local anesthetic lidocaine preceding surgery yielded significant survival benefits for patients with early-stage breast cancer.

The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers.

Precision medicine is a term that has been in our oncology language for years, but changes are occurring quickly. As oncology nurses, we need to learn about genomics and biomarkers and what precision medicine means for patients’ outcomes.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses pathogenic variant testing and what it means for oncology nurses.

Isabel Octaviano, RN, details her role and experiences supporting patients during clinical trials.

La-Urshular Brock, MSN, FNP-BC, CNM, discusses how a better understanding of HER2-low status may necessitate more testing for certain patients with breast cancer.

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.

Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.